Otsuka Holdings (4578) · InitiativeRestated
Expansion of the Overseas Active Pharmaceutical Ingredient Supply Business Through the Acquisition of Cefixime
First written in FY2019-Q2. 2 of 3 entries say "Restated". Latest entry: FY2020-Q3.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
Monetizing international sales expansion and active pharmaceutical ingredient supplyA theme 3 companies write about · 0 as a headwind · 3 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020-Q3RestatedAnnual report
「The fine chemicals segment reported higher revenue year on year, mainly from revenue related to the supply of active pharmaceutical ingredients to overseas licensees of cefixime acquired in June 2019.」
The active pharmaceutical ingredient supply business for overseas licensees of cefixime acquired in June 2019 continued to contribute to higher revenue. - FY2019-Q3RestatedAnnual report
「The fine chemicals segment reported higher revenue, mainly from revenue related to the supply of active pharmaceutical ingredients to overseas licensees of cefixime acquired in June 2019.」
The active pharmaceutical ingredient supply business for overseas licensees of cefixime, acquired in June 2019, continued to contribute to higher revenue. - FY2019-Q2First statedAnnual report
「The fine chemicals segment reported higher revenue, mainly from revenue related to the supply of active pharmaceutical ingredients to overseas licensees of cefixime acquired in June 2019.」
The supply business for active pharmaceutical ingredients to overseas licensees of cefixime was acquired in June 2019 and is listed as a factor contributing to higher revenue in Other businesses.